{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:02:18Z","timestamp":1761058938161},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2009,2,13]],"date-time":"2009-02-13T00:00:00Z","timestamp":1234483200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["World J Urol"],"published-print":{"date-parts":[[2009,6]]},"DOI":"10.1007\/s00345-009-0377-1","type":"journal-article","created":{"date-parts":[[2009,6,9]],"date-time":"2009-06-09T07:37:56Z","timestamp":1244533076000},"page":"331-335","source":"Crossref","is-referenced-by-count":32,"title":["The novel use of intravesical docetaxel for the treatment of non-muscle invasive bladder cancer refractory to BCG therapy: a single institution experience"],"prefix":"10.1007","volume":"27","author":[{"given":"LaMont J.","family":"Barlow","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James M.","family":"McKiernan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitchell C.","family":"Benson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,2,13]]},"reference":[{"key":"377_CR1","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1097\/00000478-199812000-00001","volume":"22","author":"JI Epstein","year":"1998","unstructured":"Epstein JI, Amin MB, Reuter VR et al (1998) The World Health Organization\/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder Bladder Consensus Conference Committee. Am J Surg Pathol 22:1435. doi: 10.1097\/00000478-199812000-00001","journal-title":"Am J Surg Pathol"},{"key":"377_CR2","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S0022-5347(17)58737-6","volume":"116","author":"A Morales","year":"1976","unstructured":"Morales A, Eidinger D, Bruce AW (1976) Intracavitary bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol 116:180","journal-title":"J Urol"},{"key":"377_CR3","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0022-5347(17)52736-6","volume":"128","author":"SA Brosman","year":"1982","unstructured":"Brosman SA (1982) Experience with bacillus Calmette-Guerin in patients with superficial bladder carcinoma. J Urol 128:27","journal-title":"J Urol"},{"key":"377_CR4","doi-asserted-by":"crossref","unstructured":"Smith JA Jr, Labasky RF, Cockett AT et al (1999) Bladder cancer clinical guidelines panel summary report on the management of nonmuscle invasive bladder cancer (stages Ta, T1 and TIS). The American Urological Association. J Urol 162:1697. doi: 10.1016\/S0022-5347(05)68208-0","DOI":"10.1016\/S0022-5347(05)68208-0"},{"key":"377_CR5","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/S0022-5347(17)43959-0","volume":"137","author":"WJ Catalona","year":"1987","unstructured":"Catalona WJ, Hudson MA, Gillen DP et al (1987) Risks and benefits of repeated courses of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer. J Urol 137:220","journal-title":"J Urol"},{"key":"377_CR6","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1200\/JCO.2005.03.1161","volume":"24","author":"JM McKiernan","year":"2006","unstructured":"McKiernan JM, Masson P, Murphy AM et al (2006) Phase I trial of intravesical docetaxel in the management of superficial bladder cancer refractory to standard intravesical therapy. J Clin Oncol 24:3075. doi: 10.1200\/JCO.2005.03.1161","journal-title":"J Clin Oncol"},{"key":"377_CR7","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1038\/bjc.1998.681","volume":"78","author":"R Wit de","year":"1998","unstructured":"de Wit R, Kruit WH, Stoter G et al (1998) Docetaxel (Taxotere): an active agent in metastatic urothelial cancer; results of a Phase II study in non-chemotherapy-pretreated patients. Br J Cancer 78:1342","journal-title":"Br J Cancer"},{"key":"377_CR8","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1200\/JCO.1999.17.8.2341","volume":"17","author":"S Chan","year":"1999","unstructured":"Chan S, Friedrichs K, Noel D et al (1999) Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol 17:2341","journal-title":"J Clin Oncol"},{"key":"377_CR9","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","volume":"351","author":"IF Tannock","year":"2004","unstructured":"Tannock IF, de Wit R, Berry WR et al (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502. doi: 10.1056\/NEJMoa040720","journal-title":"N Engl J Med"},{"key":"377_CR10","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1007\/s00345-002-0275-2","volume":"20","author":"F Calabro","year":"2002","unstructured":"Calabro F, Sternberg CN (2002) New drugs and new approaches for the treatment of metastatic urothelial cancer. World J Urol 20:158","journal-title":"World J Urol"},{"key":"377_CR11","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","volume":"163","author":"DL Lamm","year":"2000","unstructured":"Lamm DL, Blumenstein BA, Crissman JD et al (2000) Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol 163:1124. doi: 10.1016\/S0022-5347(05)67707-5","journal-title":"J Urol"},{"key":"377_CR12","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.eururo.2007.02.063","volume":"52","author":"MG Friedrich","year":"2007","unstructured":"Friedrich MG, Pichlmeier U, Schwaibold H et al (2007) Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with bacillus Calmette-Guerin (BCG) in patients with non-muscle-invasive bladder carcinoma. Eur Urol 52:1123. doi: 10.1016\/j.eururo.2007.02.063","journal-title":"Eur Urol"},{"key":"377_CR13","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","volume":"53","author":"EL Kaplan","year":"1958","unstructured":"Kaplan EL, Meier P (1958) Nonparametric estimation of incomplete observations. J Am Stat Assoc 53:457. doi: 10.2307\/2281868","journal-title":"J Am Stat Assoc"},{"key":"377_CR14","unstructured":"Jones JS, Campbell SC (2006) Non-muscle-invasive bladder cancer (Ta, T1, and CIS). In: Wein AJ, Kavoussi LR, Novick AC et al (eds) Campbell-Welsh urology, vol 3, Saunders, Philadelphia. pp 2447\u20132467"},{"key":"377_CR15","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/S0022-5347(17)37452-9","volume":"147","author":"HW Herr","year":"1992","unstructured":"Herr HW, Wartinger DD, Fair WR et al (1992) Bacillus Calmette-Guerin therapy for superficial bladder cancer: a 10-year followup. J Urol 147:1020","journal-title":"J Urol"},{"key":"377_CR16","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1097\/01.ju.0000141245.08456.1a","volume":"172","author":"GS Palapattu","year":"2004","unstructured":"Palapattu GS, Haisfield-Wolfe ME, Walker JM et al (2004) Assessment of perioperative psychological distress in patients undergoing radical cystectomy for bladder cancer. J Urol 172:1814. doi: 10.1097\/01.ju.0000141245.08456.1a","journal-title":"J Urol"},{"key":"377_CR17","doi-asserted-by":"crossref","first-page":"3185","DOI":"10.1200\/JCO.2002.20.15.3185","volume":"20","author":"ED Crawford","year":"2002","unstructured":"Crawford ED (2002) Intravesical therapy for superficial cancer: need for more options. J Clin Oncol 20:3185","journal-title":"J Clin Oncol"},{"key":"377_CR18","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0090-4295(91)80073-G","volume":"37","author":"RJ Babaian","year":"1991","unstructured":"Babaian RJ, Smith DB (1991) Effect of ileal conduit on patients\u2019 activities following radical cystectomy. Urology 37:33. doi: 10.1016\/0090-4295(91)80073-G","journal-title":"Urology"},{"key":"377_CR19","first-page":"765","volume":"21","author":"M Huncharek","year":"2001","unstructured":"Huncharek M, McGarry R, Kupelnick B (2001) Impact of intravesical chemotherapy on recurrence rate of recurrent superficial transitional cell carcinoma of the bladder: results of a meta-analysis. Anticancer Res 21:765","journal-title":"Anticancer Res"},{"key":"377_CR20","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/S0022-5347(01)64484-7","volume":"158","author":"K Kurth","year":"1997","unstructured":"Kurth K, Tunn U, Ay R et al (1997) Adjuvant chemotherapy for superficial transitional cell bladder carcinoma: long-term results of a European Organization for Research and Treatment of Cancer randomized trial comparing doxorubicin, ethoglucid and transurethral resection alone. J Urol 158:378. doi: 10.1016\/S0022-5347(01)64484-7","journal-title":"J Urol"},{"key":"377_CR21","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/S0090-4295(96)00621-8","volume":"49","author":"RE Greenberg","year":"1997","unstructured":"Greenberg RE, Bahnson RR, Wood D et al (1997) Initial report on intravesical administration of N-trifluoroacetyladriamycin-14-valerate (AD 32) to patients with refractory superficial transitional cell carcinoma of the urinary bladder. Urology 49:471. doi: 10.1016\/S0090-4295(96)00621-8","journal-title":"Urology"},{"key":"377_CR22","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S0094-0143(21)00419-5","volume":"19","author":"JB Thrasher","year":"1992","unstructured":"Thrasher JB, Crawford ED (1992) Complications of intravesical chemotherapy. Urol Clin North Am 19:529","journal-title":"Urol Clin North Am"},{"key":"377_CR23","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.eururo.2003.09.014","volume":"45","author":"JA Witjes","year":"2004","unstructured":"Witjes JA, van der Heijden AG, Vriesema JL et al (2004) Intravesical gemcitabine: a phase and pharmacokinetic study. Eur Urol 45:182. doi: 10.1016\/j.eururo.2003.09.014","journal-title":"Eur Urol"},{"key":"377_CR24","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1200\/JCO.2005.05.2720","volume":"24","author":"G Dalbagni","year":"2006","unstructured":"Dalbagni G, Russo P, Bochner B et al (2006) Phase II trial of intravesical gemcitabine in bacille Calmette-Guerin-refractory transitional cell carcinoma of the bladder. J Clin Oncol 24:2729. doi: 10.1200\/JCO.2005.05.2720","journal-title":"J Clin Oncol"},{"key":"377_CR25","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s002800050660","volume":"40","author":"D Song","year":"1997","unstructured":"Song D, Wientjes MG, Au JL (1997) Bladder tissue pharmacokinetics of intravesical taxol. Cancer Chemother Pharmacol 40:285. doi: 10.1007\/s002800050660","journal-title":"Cancer Chemother Pharmacol"},{"key":"377_CR26","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1136\/jcp.2003.009696","volume":"57","author":"G Nabi","year":"2004","unstructured":"Nabi G, Greene D, O\u2019Donnell MO (2004) Suspicious urinary cytology with negative evaluation for malignancy in the diagnostic investigation of haematuria: how to follow up? J Clin Pathol 57:365. doi: 10.1136\/jcp.2003.009696","journal-title":"J Clin Pathol"},{"key":"377_CR27","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/S0022-5347(01)65570-8","volume":"156","author":"HW Herr","year":"1996","unstructured":"Herr HW, Cookson MS, Soloway SM (1996) Upper tract tumors in patients with primary bladder cancer followed for 15\u00a0years. J Urol 156:1286. doi: 10.1016\/S0022-5347(01)65570-8","journal-title":"J Urol"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-009-0377-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00345-009-0377-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-009-0377-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,7]],"date-time":"2021-10-07T04:50:40Z","timestamp":1633582240000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00345-009-0377-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,2,13]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,6]]}},"alternative-id":["377"],"URL":"https:\/\/doi.org\/10.1007\/s00345-009-0377-1","relation":{},"ISSN":["0724-4983","1433-8726"],"issn-type":[{"value":"0724-4983","type":"print"},{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,2,13]]}}}